Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
NCT00372775
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients with radiologically proven brain metastases secondary to non-small cell lung cancer
- Received previous whole brain radiation therapy and none, 1 or 2 prior systemic therapy for the treatment of advanced/metastatic non-small cell lung cancer
- Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or
leptomeningeal disease.
- Brain metastases >4 cm in any linear direction
- Intracranial or intratumoral hemorrhage
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Gainesville, Florida
- Gothenburg,
- Jönköping,
- Kalmar,
- Linköping,
- Lund,
- Malmö,
- Skövde,
- Trollhättan,
- Uddevalla,
- Umeå,
- Uppsala,
- Ystad,
- Örebro,
- St. Louis, Missouri
- Altamonte Springs, Florida
- Bonita Springs, Florida
- Bradenton, Florida
- Brandon, Florida
- Cape Coral, Florida
- Clearwater, Florida
- Fleming Island, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Largo, Florida
- Lecanto, Florida
- Naples, Florida
- New Port Richey, Florida
- Ocala, Florida
- Orange City, Florida
- Orlando, Florida
- Port Charlotte, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Sarasota, Florida
- Spring Hill, Florida
- Tallahassee, Florida
- Tampa, Florida
- Tavares, Florida
- The Villages, Florida
- Venice, Florida
- Winter Park, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Johns Creek, Georgia
- Overland Park, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Creve Coeur, Missouri
- Independence, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- New York, New York
- New York, New York
- Durham, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Gahanna, Ohio
- Lewis Center, Ohio
- Clackamas, Oregon
- Newberg, Oregon
- Chattanooga, Tennessee
- Cleveland, Tennessee
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hendersonville, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Kingwood, Texas
- The Woodlands, Texas
- Roma, Lazio
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Napoli,
- Torino,
- Barcelona,
- Cordoba,
- Cordoba,
- Esplugues de Llobregat,
- L'Hospitalet,
- Malaga,
- Sevilla,
- Los Angeles, California
- Santa Monica, California
- Norwich, Connecticut
- Norwich, Connecticut
- Norwich, Connecticut
- Putnam, Connecticut
- Fort Myers, Florida
- Saint Petersburg, Florida
- Tallahassee, Florida
- Venice, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Overland Park, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Chelsea, Massachusetts
- Danvers, Massachusetts
- Marlborough, Massachusetts
- Stoneham, Massachusetts
- Stoneham, Massachusetts
- Waltham, Massachusetts
- Independence, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Basking Ridge, New Jersey
- Hackensack, New Jersey
- Montvale, New Jersey
- Bronx, New York
- Bronx, New York
- Bronx, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Portland, Oregon
- Portland, Oregon
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- York, Pennsylvania
- York, Pennsylvania
- Chattanooga, Tennessee
- Chattanooga, Tennessee
- Houston, Texas
- Houston, Texas
- Shenandoah, Texas
- Seattle, Washington
- Faenza, Emilia-romagna
- Lugo, Emilia-romagna
- Ravenna, Emilia-romagna
- Ravenna, Emilia-romagna
- Rimini, Emilia-romagna
- Milano, Lombardia
- Milano, Lombardia
- Napoli, Naples
- Cattolica, Rimini
- Orbassano, Torino
- Bologna,
- Milano,
- Naples,
- Goyang-si, Gyeonggido
- Jeonnam,
- Seoul,
- Seoul,
- Seoul,
- Amsterdam, Noord-holland
- Amsterdam, Noord-holland
- Groningen,
- Hospitalet de Llobregat, Barcelona
- L'Hospitalet de Llobregat, Barcelona
- L'Hospitalet de Llobregat, Barcelona
- Majadahonda, Madrid
- Malaga, Málaga
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Hospitalet de Llobregat,
- Madrid,
- Madrid,
- Sevilla,
- Sevilla,
- Sevilla,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases | |||
Official Title ICMJE | A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases | |||
Brief Summary | This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Non-Small Cell Lung Cancer | |||
Intervention ICMJE | Drug: Sunitinib
Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity Other Name: Sutent | |||
Study Arms ICMJE | Experimental: Sunitinib
Intervention: Drug: Sunitinib | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 66 | |||
Original Enrollment ICMJE | 60 | |||
Actual Study Completion Date ICMJE | December 2009 | |||
Actual Primary Completion Date | December 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | France, Italy, Spain, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00372775 | |||
Other Study ID Numbers ICMJE | A6181092 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |